Picture of Beam Therapeutics logo

BEAM — Beam Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Beam Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

* Beam Therapeutics Inc  BEAM.OQ  reported a quarterly
adjusted
loss of $1.17​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-1.22.  The mean expectation of
seventeen analysts for the quarter was for a loss of $1.16 per
share. Wall Street expected results to range from $-1.35 to -94
cents per share.
    * Revenue fell 17% to $14.27 million from a year ago;
analysts
expected $14.50 million. 
    * Beam Therapeutics Inc's reported EPS for the quarter was a
loss
of $1.17​.
    * The company reported a quarterly loss of $96.67 million.
    * Beam Therapeutics Inc shares had fallen by 2.3% this
quarter and
lost 12.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 9
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Beam Therapeutics
Inc is $49.00 
This summary was machine generated from LSEG data November 6 at
05:14 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -1.16          -1.17          Missed
 Jun. 30 2024      -1.13          -1.11          Beat
 Mar. 31 2024      -1.42          -1.21          Beat
 Dec. 31 2023      -1.01          1.73           Beat

Recent news on Beam Therapeutics

See all news